Coherus Oncology earnings were -$132.1M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest CHRS earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$20.6M, down 46.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, CHRS reported annual earnings of $168.0M, with 489.4% growth. The next CHRS earnings date is Nov 5, 2026.
What were Coherus Oncology's earnings last quarter?
On CHRS's earnings call on Aug 5, 2026, Coherus Oncology (NASDAQ: CHRS) reported Q2 2026 earnings per share (EPS) of -$0.13, up 105.06% year over year. Total CHRS earnings for the quarter were -$20.63 million. In the same quarter last year, Coherus Oncology's earnings per share (EPS) was $2.57.
The next CHRS earnings call is Nov 5, 2026. Add CHRS to your watchlist to be reminded of Coherus Oncology's next earnings date.
Is Coherus Oncology profitable or losing money?
As of the last Coherus Oncology earnings report, Coherus Oncology is currently losing money. Coherus Oncology's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$132.13 million, a 173.51% decrease year over year.
What was CHRS's earnings growth in the past year?
As of Coherus Oncology's earnings date in Aug 5, 2026, Coherus Oncology's earnings has grown year over year. CHRS earnings in the past year totalled -$132.13 million.
What are Coherus Oncology's earnings expectations?
The current EPS estimate for Coherus Oncology's earnings report in Nov 5, 2026 is -$0.22.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.